Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company had a total market capitalization of 10.623 billion yuan [1]. Market Dynamics - The company benefits from trends in the pet economy, medical devices, and water conservancy, as well as the depreciation of the RMB, which has positively impacted its overseas revenue, accounting for 55.26% of total revenue [3][4]. - The stock has experienced a recent increase in trading activity, with a turnover rate of 2.32% and a trading volume of 33.54 million yuan on November 6 [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which represents a decrease of 388,200 shares compared to the previous period [9].

Core Viewpoint - The company, Shantou Ultrasound Instrument Research Institute Co., Ltd., is experiencing fluctuations in stock performance and is involved in the medical imaging and industrial non-destructive testing equipment sectors, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasound Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. The company specializes in the research, development, production, and sales of medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company had a total of 17,000 shareholders, a decrease of 23.90% from the previous period, with an average of 3,438 circulating shares per person, an increase of 39.99% [8]. Market Activity - On October 30, the company's stock price fell by 3.20%, with a trading volume of 79.15 million yuan and a turnover rate of 5.57%, resulting in a total market capitalization of 10.366 billion yuan [1]. - The main capital inflow for the day was negative at 13.40 million yuan, indicating a trend of capital reduction over the past three days [4]. Institutional Holdings - As of September 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, a decrease of 388,200 shares from the previous period. Other notable shareholders include Yuanxin Yongfeng Medical Health A and Hong Kong Central Clearing Limited [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company's overseas revenue accounted for 55.26%, benefiting from the depreciation of the RMB [3]. Market Activity - On October 28, the company's stock rose by 0.76%, with a trading volume of 57.19 million yuan and a turnover rate of 3.90%, bringing the total market capitalization to 10.755 billion yuan [1]. - The stock has seen a net outflow of 1.2384 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pets, horses, and livestock, and engaged with industry experts on animal healthcare development [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the development of portable devices [2].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and medical device sectors, benefiting from the depreciation of the RMB and its recent listing as a new stock under the registration system [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to the parent company of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a shareholder count of 22,300, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Activity - On October 23, the company's stock rose by 2.26%, with a trading volume of 64.68 million yuan and a turnover rate of 4.50%, bringing the total market capitalization to 10.657 billion yuan [1]. - The stock has seen a net inflow of 3.62 million yuan from major investors today, accounting for 0.06% of the total, with the industry ranking at 9 out of 131 [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging products at the 97th WVC annual conference, engaging with industry experts on the development of animal healthcare [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the capabilities of portable devices [2][3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a shareholder count of 22,300, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% to 2,456 shares [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. Shareholder Structure - As of June 30, 2025, the top circulating shareholders include Huabao Zhongzheng Medical ETF, Southern Zhongzheng 1000 ETF, and Hong Kong Central Clearing Limited, with several new institutional shareholders entering [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3][7]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company is involved in various concept sectors, including nuclear power, medical devices, smart healthcare, and newly listed stocks [7]. Recent Developments - The company participated in the 97th WVC Annual Conference from March 3 to 5, 2025, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices, enabling remote image transmission and online diagnostic guidance through its "Mali Doctor" platform [2][3]. Stock Performance - On September 4, 2025, the company's stock price fell by 1.18%, with a trading volume of 84.1682 million yuan and a turnover rate of 5.71%, resulting in a total market capitalization of 10.738 billion yuan [1]. - The average trading cost of the stock is 27.20 yuan, with the current price approaching a resistance level of 25.49 yuan, indicating potential for upward movement if this level is breached [6].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. Group 2: Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, a year-on-year increase of 18.50% [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On September 1, the company's stock rose by 0.69%, with a trading volume of 95.83 million yuan and a turnover rate of 6.26%, resulting in a total market capitalization of 11.27 billion yuan [1]. - The stock has seen a net outflow of 205,000 yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on the pet economy and smart medical technology [2][3][7]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices, and is recognized as a national key high-tech enterprise [7]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the number of shareholders decreased by 16.65% to 22,300, while the average circulating shares per person increased by 19.98% to 2,456 shares [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [8]. Group 3: Market Dynamics - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company participated in the 97th WVC annual meeting, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and gained valuable insights from industry experts [2]. Group 4: Technical Analysis - The average trading cost of the company's shares is 27.99 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6]. - The current stock price is near a support level of 26.85 yuan, and if this support is breached, it may trigger a downward trend [6]. Group 5: Investment Sentiment - The stock experienced a decline of 2.68% on August 27, with a trading volume of 206 million yuan and a turnover rate of 12.85%, resulting in a total market capitalization of 11.514 billion yuan [1]. - The main capital flow showed a net outflow of 4.67 million yuan, indicating a reduction in main capital positions over three consecutive days [4][5].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 50.32%, industrial ultrasound 19.04%, X-ray 16.30%, accessories 12.52%, and others 1.82% [7]. Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 98.43 million yuan, representing a year-on-year growth of 28.69%, and a net profit attributable to the parent company of 39.32 million yuan, with a year-on-year increase of 47.70% [8]. - As of March 31, 2025, the company had 26,800 shareholders, a decrease of 46.67% from the previous period, with an average of 2,047 circulating shares per person, an increase of 87.50% [8]. Market Activity - On August 20, the company's stock price increased by 0.11%, with a trading volume of 212 million yuan and a turnover rate of 12.93%, resulting in a total market capitalization of 12.087 billion yuan [1]. - The main net inflow of funds today was 8.9166 million yuan, accounting for 0.04%, with the industry ranking at 9 out of 131 [4]. Product and Technology Development - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pet, equine, and livestock health care [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR equipment, enabling remote transmission of images and reports through 5G networks, and offers online diagnostic guidance through the "Mali Doctor" platform [2][3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and medical device sectors, benefiting from the depreciation of the RMB and its recent listing as a new stock under the registration system [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The main business revenue composition includes: medical ultrasound 50.32%, industrial ultrasound 19.04%, X-ray 16.30%, accessories 12.52%, and others 1.82% [7]. Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 98.43 million, representing a year-on-year growth of 28.69%, and a net profit attributable to the parent company of 39.32 million, with a year-on-year increase of 47.70% [8]. - As of March 31, 2025, the company had a total of 26,800 shareholders, a decrease of 46.67% from the previous period, with an average of 2,047 circulating shares per person, an increase of 87.50% [8]. Market Activity - On August 18, the company's stock rose by 2.16%, with a trading volume of 240 million and a turnover rate of 14.56%, bringing the total market capitalization to 12.177 billion [1]. - The stock has seen a net outflow of 17.76 million from major investors today, with a continuous three-day trend of being reduced by major funds [4][5]. Product and Technology Development - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual conference, focusing on pet, equine, and livestock health care [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the development of portable devices [2][3].